Opinion|Videos|October 7, 2024
Care Coordination for High-Risk CRM Patients
Key Takeaways
- Future guidelines may integrate emerging evidence and novel therapeutic strategies for CKD, T2D, and CVD management.
- Personalized treatment plans considering the interplay between CKD, T2D, and CVD could be emphasized.
Medical experts examine strategies for care coordination in high-risk patients with cardiometabolic conditions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you define effective care coordination in the context of high-risk CRM patients?
- What are the key elements of a successful care coordination program for these patients?
- Why is this so challenging at the large health systems represented here and around the country?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
